PMID- 38465342
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240312
IS  - 2391-5412 (Electronic)
IS  - 2391-5412 (Linking)
VI  - 19
IP  - 1
DP  - 2024
TI  - Role of serum B-cell-activating factor and interleukin-17 as biomarkers in the 
      classification of interstitial pneumonia with autoimmune features.
PG  - 20220814
LID - 10.1515/biol-2022-0814 [doi]
LID - 20220814
AB  - Interstitial pneumonia with autoimmune features (IPAF) is a type of interstitial 
      lung disease (ILD) with immune features that do not meet the diagnostic criteria 
      for specific connective tissue diseases (CTDs). This retrospective case-control 
      study investigated the role of serum B-cell-activating factor of the tumor 
      necrosis factor family (BAFF) and interleukin (IL)-17 as biomarkers for IPAF. The 
      differences in serum BAFF, IL-17, and IL-10 were compared among patients with 
      idiopathic pulmonary fibrosis (IPF), IPAF, ILD associated with CTD (CTD-ILD), and 
      healthy controls. The patients were treatment naive. The correlations of BAFF 
      with IL-10, IL-17, and pulmonary function were analyzed. The classifiable value 
      of BAFF for IPAF was examined. The results showed that the serum levels of BAFF 
      and IL-17 in the IPAF and CTD-ILD groups were higher than in the IPF group. High 
      BAFF levels and high predicted diffusion capacity of the lungs for carbon 
      monoxide (DLCO) were independent predictive factors for IPAF vs IPF. In the IPAF 
      and CTD-ILD groups, serum BAFF levels were negatively correlated with predicted 
      values of forced vital capacity (FVC%) and diffusing capacity of the lungs for 
      carbon monoxide (DLCO%) and positively correlated with serum IL-17 and IL-10 
      levels. The cutoff value of combined BAFF and IL-17 was 0.704, and the 
      sensitivity and specificity for classifying IPAF were 78.9 and 95.7%, 
      respectively. In conclusion, combining serum BAFF and IL-17 as a biomarker may 
      have classifiable value in differentiating IPAF from other forms of ILD.
CI  - (c) 2024 the author(s), published by De Gruyter.
FAU - Zhao, Lihong
AU  - Zhao L
AD  - Department of Respiratory and Critical Care Medicine, Tianjin First Central 
      Hospital, Tianjin, 300192, China.
FAU - Liu, Li
AU  - Liu L
AD  - Department of Respiratory and Critical Care Medicine, Tianjin First Central 
      Hospital, Tianjin, 300192, China.
FAU - Liu, Yehua
AU  - Liu Y
AD  - Department of Clinical Laboratory, Tianjin First Central Hospital, Tianjin, 
      300192, China.
FAU - Zheng, Hong
AU  - Zheng H
AD  - Department of Respiratory and Critical Care Medicine, Tianjin First Central 
      Hospital, Tianjin, 300192, China.
FAU - Jiang, Ping
AU  - Jiang P
AD  - Department of Respiratory and Critical Care Medicine, Tianjin First Central 
      Hospital, 24 Fukang Road, Nankai District, Tianjin, 300192, China.
LA  - eng
PT  - Journal Article
DEP - 20240208
PL  - Poland
TA  - Open Life Sci
JT  - Open life sciences
JID - 101669614
PMC - PMC10921473
OTO - NOTNLM
OT  - BAFF
OT  - inflammatory mechanism
OT  - interleukin-17
OT  - interstitial lung disease
OT  - pneumonia autoimmune features
COIS- Conflict of interest: Authors state no conflict of interest.
EDAT- 2024/03/11 06:43
MHDA- 2024/03/11 06:44
PMCR- 2024/02/08
CRDT- 2024/03/11 04:49
PHST- 2023/03/10 00:00 [received]
PHST- 2023/11/15 00:00 [revised]
PHST- 2023/11/17 00:00 [accepted]
PHST- 2024/03/11 06:44 [medline]
PHST- 2024/03/11 06:43 [pubmed]
PHST- 2024/03/11 04:49 [entrez]
PHST- 2024/02/08 00:00 [pmc-release]
AID - biol-2022-0814 [pii]
AID - 10.1515/biol-2022-0814 [doi]
PST - epublish
SO  - Open Life Sci. 2024 Feb 8;19(1):20220814. doi: 10.1515/biol-2022-0814. 
      eCollection 2024.